Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 651 - 675 of 1990 in total

Rizatriptan

Rizatriptan is a second-generation triptan and a selective 5-HT1B and 5-HT1D receptor agonist. Used in the treatment of migraines, rizatriptan was first approved in the US in 1998. Rizatriptan is available in oral tablets, orally disintegrating tablets (wafers), and oral film formulations.
Approved
Matched Description: … Rizatriptan is a second-generation triptan [A258918] and a selective 5-HT1B and 5-HT1D receptor ... [L46018] Rizatriptan is available in oral tablets, orally disintegrating tablets (wafers), and oral film …
Matched Categories: … Serotonin-1b and Serotonin-1d Receptor Agonist …

Clascoterone

Clascoterone (cortexolone 17α-propionate, CB-03-01) is a novel antagonist of androgen receptors. It binds to androgen receptors with high affinity. By competing with androgens for binding to androgen receptors, clascoterone works by blocking the androgen receptor signalling cascades that promote acne pathogenesis, such as sebaceous gland proliferation, excess sebum production, and...
Approved
Investigational
Matched Description: … female patients 12 years and older. ... FDA approved clascoterone for the first-in-class topical treatment of acne (acne vulgaris) in male and ... cascades that promote acne pathogenesis, such as sebaceous gland proliferation, excess sebum production, and …
Matched Categories: … Hormones, Hormone Substitutes, and Hormone Antagonists …

Milnacipran

Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment of depression [F3928, F3934, A175786, A175951]. Furthermore, in 2009 the US FDA approved milnacipran for the additional indication of...
Approved
Investigational
Matched Description: … Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents ... in this category was originally developed for and continues to be approved and indicated for the treatment ... unique characteristic among SNRIs to elicit a relatively balanced reuptake inhibition of both serotonin and …
Matched Categories: … Milnacipran and enantiomer ... Serotonin and Noradrenaline Reuptake Inhibitors …

Lumacaftor

Lumacaftor is a drug used in combination with DB08820 as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic...
Approved
Matched Description: … Approved for use by the Food and Drug Administration in July 2015 and by Health Canada in January 2016 ... and trafficking of mature protein to the cell surface. ... consequently abnormal fluid and ion transport across cell membranes. …
Matched Categories: … ivacaftor and lumacaftor …

Midazolam

Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called benzodiazepines. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazolam is available by...
Approved
Illicit
Matched Description: … and endoscopic procedures as pre-anesthetic medication, and as an adjunct to local anesthesia. ... This drug is unique from others in this class due to its rapid onset of effects and short duration of ... short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and …
Matched Categories: … Hypnotics and Sedatives ... Benzodiazepine hypnotics and sedatives ... Benzodiazepines and benzodiazepine derivatives …

Tegaserod

Novartis' brand name Zelnorm (tegaserod) had originally received approval from the US FDA in 2002 for the treatment of irritable bowel syndrome with constipation (IBS-C).[L5918,F4229] It was, however, voluntarily withdrawn from widespread use in the US market in 2007 after concerns arose over the possibility that tegaserod could potentially cause...
Approved
Investigational
Withdrawn
Matched Description: … the unique mechanism of action of acting on serotonin-4 (5-HT(4)) receptors in smooth muscle cells and ... the gastrointestinal wall to facilitate actions like esophageal relaxation, peristaltic gut movement, and ... re-approval' of tegaserod for treatment of IBS-C specifically in female patients less than 65 years of age and …
Matched Categories: … Alimentary Tract and Metabolism …

Cysteamine

Cystinosis is a rare disease caused by mutations in the CTNS gene that encodes for cystinosin, a protein responsible for transporting cystine out of the cell lysosome. A defect in cystinosin function is followed by cystine accumulation throughout the body, especially the eyes and kidneys. Several preparations of cysteamine exist...
Approved
Investigational
Matched Description: … in cystinosin function is followed by cystine accumulation throughout the body, especially the eyes and ... preparations of cysteamine exist for the treatment of cystinosis manifestations, some in capsule form, and ... L15616] In particular, cystine deposits on the eye can cause significant discomfort throughout the day and …
Matched Categories: … Amino Acids and Derivatives ... Alimentary Tract and Metabolism …

Enzalutamide

Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be...
Approved
Matched Description: … receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and ... A252667] Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and ... [A252667] Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Hormone Antagonists and Related Agents …

Tipiracil

Tipiracil is a thymidine phosphorylase inhibitor. It is used in combination with trifluridine, in a ratio of 1:0.5, to form TAS-102. The main function of Tipiracil in TAS-102 is to increase trifluridine bioavailability by inhibiting its catabolism. TAS-102 is indicated for the treatment of metastatic colorectal cancer which has been...
Approved
Investigational
Matched Description: … metastatic colorectal cancer which has been previously treated with fluoropyrimidine-, oxaliplatin- and …

Esketamine

Major depressive disorder (MDD) is a significant cause of disability worldwide and the most common illness preceding suicide.[L5596,A175462] On March 5, 2019, the nasal spray drug, esketamine, also known as Spravato (by Janssen Pharmaceuticals), was approved by the FDA for treatment-resistant major depression. Esketamine is the s-enantiomer of Ketamine. Ketamine...
Approved
Investigational
Matched Description: … Major depressive disorder (MDD) is a significant cause of disability worldwide and the most common illness ... The intranasal route of administration for this drug allows for easy administration and a fast onset ... disorder who have not experienced an improvement in symptoms despite treatment with various medications and …

Quizartinib

Quizartinib is an oral and potent fms-like tyrosine kinase 3 (FLT3) inhibitor and it is the first drug developed specifically targeting FLT3, as other agents with FLT3 inhibition activities were investigated with other targets in mind. Additionally, quizartinib also demonstrates inhibitory activity toward FLT3 with internal tandem duplication (ITD), although...
Approved
Investigational
Matched Description: … Quizartinib is an oral and potent fms-like tyrosine kinase 3 (FLT3) inhibitor and it is the first drug ... thus poorer overall survival and higher risk of relapse. ... anthracycline induction and standard cytarabine consolidation, followed by a maintenance monotherapy …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Eslicarbazepine acetate

Eslicarbazepine acetate (ESL) is an anticonvulsant medication approved for use in Europe, the United States and Canada as an adjunctive therapy for partial-onset seizures that are not adequately controlled with conventional therapy. Eslicarbazepine acetate is a prodrug that is rapidly converted to eslicarbazepine, the primary active metabolite in the body....
Approved
Matched Description: … Eslicarbazepine acetate (ESL) is an anticonvulsant medication approved for use in Europe, the United States and ... Eslicarbazepine acetate is marketed as Aptiom in North America and Zebinix or Exalief in Europe. ... , but it is known that it does exert anticonvulsant activity by inhibiting repeated neuronal firing and …
Matched Categories: … Eslicarbazepine and prodrugs …

Choline C-11

Choline C 11 Injection is a radioactive diagnostic agent for positron emission tomography (PET) imaging of pat ients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized tomography (CT) or magnetic resonance imaging.
Approved
Matched Description: … for positron emission tomography (PET) imaging of pat ients with suspected prostate cancer recurrence and …

Linzagolix

Linzagolix is a non-peptide, selective antagonist of the gonadotropin-releasing hormone (GnRH) receptor. It has been studied for the treatment of estrogen-dependent conditions such as uterine fibroids and endometriosis.[A253642,A253647] It is similar to other GnRH receptor antagonists like cetrorelix, relugolix, and elagolix. Uterine fibroids occur in >70% of women of reproductive...
Approved
Matched Description: … , and reproductive dysfunction. ... [A253642,A253647] It is similar to other GnRH receptor antagonists like [cetrorelix], [relugolix], and ... Uterine fibroids occur in >70% of women of reproductive age, and when symptomatic are associated with …
Matched Categories: … Pituitary and Hypothalamic Hormones and Analogues ... Sex Hormones and Insulins …

Secukinumab

Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan...
Approved
Matched Description: … Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory ... in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and ... chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Cobicistat

Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic exposure of coadministered agents that are metabolized...
Approved
Matched Description: … Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human ... exposure of anti-retrovirals (ARVs) without increasing dosage allows for better treatment outcomes and ... activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and …
Matched Categories: … darunavir and cobicistat ... atazanavir and cobicistat ... Metabolic Side Effects of Drugs and Substances ... emtricitabine, tenofovir alafenamide, darunavir and cobicistat ... emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat …

Aminolevulinic acid

A compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. It is used as a photochemotherapy for actinic keratosis. [PubChem]
Approved
Matched Description: … A compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Skin and Mucous Membrane Agents ... Antineoplastic and Immunomodulating Agents …

Prasugrel

Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing...
Approved
Matched Description: … and pharmacologically related to clopidogrel and ticlopidine. ... Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada ... As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. …
Matched Categories: … Blood and Blood Forming Organs …

Agomelatine

Agomelatine is structurally closely related to melatonin. Agomelatine is a potent agonist at melatonin receptors and an antagonist at serotonin-2C (5-HT2C) receptors, tested in an animal model of depression. Agomelatine was developed in Europe by Servier Laboratories Ltd. and submitted to the European Medicines Agency (EMA) in 2005. The Committee...
Approved
Investigational
Matched Description: … The Committee for Medical Products for Human Use (CHMP) recommended refusal of marketing authorization ... Agomelatine is a potent agonist at melatonin receptors and an antagonist at serotonin-2C (5-HT2C) receptors ... Agomelatine was developed in Europe by Servier Laboratories Ltd. and submitted to the European Medicines …

Ofatumumab

Ofatumumab is a novel anti-CD20 monoclonal antibody that targets B-cells. It is an IgG1κ human monoclonal antibody produced from a recombinant murine cell line (NS0) via transgenic mouse and hybridoma technology. Ofatumumab works by recognizing antigens that are expressed on the tumour cells in certain cancers; however, the antigen is...
Approved
Matched Description: … It is an IgG1κ human monoclonal antibody produced from a recombinant murine cell line (NS0) via transgenic ... mouse and hybridoma technology. ... In February 2020, FDA and EMA approved Supplemental Biologics License Application (sBLA) and Marketing …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Pembrolizumab

Pembrolizumab is a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptors. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype containing a stabilizing S228P Fc mutation. It contains 32 cysteine residues and the complete folded molecule includes...
Approved
Matched Description: … generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human ... as interchain bonds and 23 interchain bonds. ... [A18829] It contains 32 cysteine residues and the complete folded molecule includes 4 disulfide linkages …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Ceftobiprole medocaril

Ceftobiprole medocaril is a prodrug of ceftobiprole, a fifth-generation semisynthetic cephalosporin antibacterial. Ceftobiprole is a broad-spectrum agent with demonstrated activity against both Gram-positive and Gram-negative bacteria, including antibiotic-resistant strains of Staphylcoccus aureus (methicillin-resistant Staphylococcus aureus; MRSA). The EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion...
Approved
Experimental
Investigational
Matched Description: … The EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion of ceftobiprole ... infections and bacteremia in April 2024. ... Ceftobiprole is a broad-spectrum agent with demonstrated activity against both Gram-positive and Gram-negative …

Momelotinib

Momelotinib is a Janus Kinase 1 (JAK1) and 2 (JAK2) inhibitor. It is a competitive inhibitor of JAK ATP binding. First approved by the FDA on September 15, 2023, momelotinib is used to treat myelofibrosis. Myelofibrosis (MF) is a group of myeloproliferative neoplasms characterized by abnormal proliferative hematopoietic stem cells,...
Approved
Investigational
Matched Description: … Momelotinib is a Janus Kinase 1 (JAK1) and 2 (JAK2) inhibitor. ... Clinical manifestations of MF include anemia and thrombocytosis. ... MF includes primary MF (PMF), post-polycythemia vera (PV) MF, and post-essential thrombocythemia (ET) …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Loteprednol etabonate

Loteprednol Etabonate (LE) is a topical corticoid anti-inflammatory. It is used in ophthalmic solution for the treatment of steroid responsive inflammatory conditions of the eye such as allergic conjunctivitis, uveitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, and selected infective conjunctivitides. As a nasal spray, it can...
Approved
Matched Description: … As a nasal spray, it can be used for the treatment and management of seasonal allergic rhinitis. ... , uveitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, and ... prescription LE products, however, tend to be indicated for the treatment of post-operative inflammation and …

Dalbavancin

Dalbavancin is a second-generation lipoglycopeptide antibiotic that was designed to improve on the natural glycopeptides currently available, such as vancomycin and teicoplanin [A4072, A4073]. Modifications from these older glycoprotein classes facilitated a similar mechanism of action for dalbavancin but with increased activity and once-weekly dosing [FDA Label, F2356, A4072, A4073]....
Approved
Investigational
Matched Description: … S. constellatus), and Enterococcus faecalis (vancomycin susceptible strains) [FDA Label, F2356]. ... Its use is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) ... antibiotic that was designed to improve on the natural glycopeptides currently available, such as vancomycin and …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Displaying drugs 651 - 675 of 1990 in total